Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Catalyst Pharmaceuticals Inc.

www.catalystpharma.com

Latest From Catalyst Pharmaceuticals Inc.

FDA Broke Catalyst's Orphan Exclusivity Due To Pricing, Not Clinical, Concerns, Firm Claims

Suit against agency reveals internal discussions to approve Jacobus' Ruzurgi despite Catalyst's orphan exclusivity for the same drug; Sen. Bernie Sanders urged FDA to address price of Catalyst's Firdapse (amifampridine).

FDA Legal Issues

Catalyst Will Try To Salvage Rare Disease Drug from Failed Phase III Trial

Despite a Phase III study that found no statistically significant outcomes for its endpoints for Firdapse, Catalyst will seek FDA approval for treating a subgroup of patients who showed improvement

Rare Diseases Neurology

Keeping Track: Intercept Submits OCA For NASH; Zogenix’ Fintepla Returns; US FDA Approves Bavarian Nordic Vaccine

The latest drug development news and highlights from our US FDA Performance Tracker

US FDA Performance Tracker Drug Review

Finance Watch: Two New IPOs – IGM In the US, Henlius In Hong Kong – Gross Nearly $600m

Public Company Edition: IGM raised $175m to advance its IgM antibodies and Henlius brought in $410m for its novel drug and biosimilar platforms. Also, Acadia follow-on brings in $250m, PTC sells $350m worth of stock and debt, and Karyopharm royalty deal totals $150m.

Financing Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Catalyst Pharmaceutical Partners Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Catalyst Pharmaceuticals Inc.
  • Senior Management
  • Patrick J McEnany, Chmn., Pres. & CEO
    Alicia Grande, VP, CFO & Treasurer
    Steven R Miller, PhD, COO & CSO
    Gary Ingentio, MD, PhD, CMO
    Daniel J Brennan, Chief Commercial Officer
    Jeff Del Carmen, SVP, Sales & Mktg.
    Stanley Iyadurai, VP, Clinical Dev.
  • Contact Info
  • Catalyst Pharmaceuticals Inc.
    Phone: (305) 420-3200
    355 Alhambra Cir.
    Ste. 1250
    Coral Gables, FL 33134
    USA
UsernamePublicRestriction

Register